

(FILE 'HOME' ENTERED AT 14:49:10 ON 27 SEP 2005)

FILE 'CAPLUS' ENTERED AT 14:49:21 ON 27 SEP 2005

L1 STRUCTURE uploaded

S L1

FILE 'REGISTRY' ENTERED AT 14:49:54 ON 27 SEP 2005

L2 1 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:49:54 ON 27 SEP 2005

L3 2 S L2 FULL

FILE 'REGISTRY' ENTERED AT 14:52:20 ON 27 SEP 2005

L4 STRUCTURE uploaded

FILE 'CAPLUS' ENTERED AT 14:56:12 ON 27 SEP 2005

L5 STRUCTURE uploaded

S L5

FILE 'REGISTRY' ENTERED AT 14:56:40 ON 27 SEP 2005

L6 0 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:56:42 ON 27 SEP 2005

L7 0 S L6 SSS FULL

S L5

FILE 'REGISTRY' ENTERED AT 14:57:12 ON 27 SEP 2005

L8 0 S L5 FULL

FILE 'CAPLUS' ENTERED AT 14:57:14 ON 27 SEP 2005

L9 0 S L8 FULL

L10 STRUCTURE uploaded

S L10

FILE 'REGISTRY' ENTERED AT 14:58:49 ON 27 SEP 2005

L11 0 S L10 SSS FULL

FILE 'CAPLUS' ENTERED AT 14:58:49 ON 27 SEP 2005

L12 0 S L11 SSS FULL

L13 STRUCTURE uploaded

S L13

FILE 'REGISTRY' ENTERED AT 15:01:27 ON 27 SEP 2005

L14 1 S L13

FILE 'CAPLUS' ENTERED AT 15:01:28 ON 27 SEP 2005

L15 3 S L14

S L13

FILE 'REGISTRY' ENTERED AT 15:01:38 ON 27 SEP 2005

L16 17 S L13 FULL

FILE 'CAPLUS' ENTERED AT 15:01:40 ON 27 SEP 2005

L17 1295 S L16 FULL

L18 13 S L17 AND (CYAN? OR NITRILE)


L19 1 S L18 AND REDUC?

L20 7 S L18 AND HYDRO?

L21 0 S L20 AND BASE

L22 2 S L20 AND PY<2001

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1988:466216 CAPLUS  
 DOCUMENT NUMBER: 109:66216  
 TITLE: Validity of short-term examination for antipromoters  
 of bladder carcinogenesis  
 AUTHOR(S): Kakizoe, Tadao; Takai, Kazuhiro; Tobisu, Kenichi;  
 Ohtani, Mikinobu; Sato, Shigeaki  
 CORPORATE SOURCE: Urol. Div., Natl. Cancer Cent. Hosp., Tokyo, 104,  
 Japan  
 SOURCE: Japanese Journal of Cancer Research (1988),  
 79(2), 231-5  
 CODEN: JJCREP; ISSN: 0910-5050  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Various compds. were screened for antipromoter activity in bladder  
 carcinogenesis in rats with a view to using them clin. to inhibit  
 postoperative intravesical ectopic tumor growth of superficial papillary  
 bladder cancer. Their inhibitions of the effect of Na saccharin in  
 maintaining increased agglutinability of bladder cells by Con A were  
 examined in 4-wk tests. The compds. found to inhibit the effect of  
 saccharin were  $\alpha$ -tocopherol, ascorbic acid, aspirin, all-trans aromatic  
 retinoid,  $\alpha$ -difluoromethylornithine, sodium cyanate and  
 p,p'-diaminodiphenylmethane. Considering the toxicities of some of these  
 chems., ascorbic acid and  $\alpha$ -difluoromethylornithine were concluded  
 to be the most promising for future clin. trials.  
 IT 70052-12-9,  $\alpha$ -Difluoromethylornithine  
 RL: PRP (Properties)  
 (antipromoter effects of, on bladder carcinogenesis)  
 RN 70052-12-9 CAPLUS  
 CN Ornithine, 2-(difluoromethyl)- (9CI) (CA INDEX NAME)



L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1988:146047 CAPLUS  
 DOCUMENT NUMBER: 108:146047  
 TITLE: Putrescine derivatives as substrates of spermidine  
 synthase  
 AUTHOR(S): Sarhan, S.; Dezeure, F.; Seiler, N.  
 CORPORATE SOURCE: Merrell Dow Res. Inst., Strasbourg, 67084, Fr.  
 SOURCE: International Journal of Biochemistry (1987  
 ), 19(11), 1037-47  
 CODEN: IJBOBV; ISSN: 0020-711X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Derivs. of 1,4-butanediamine (putrescine) were studied in vitro and in  
 vivo as potential substrates of spermidine synthase. Substituents in the  
 1-position decreased the reaction rate by steric hindrance, and in the  
 case of electron-withdrawing groups there was an addition decrease due to the  
 lowered basicity of the vicinal amino group. Substituents in the  
 2-position were tolerated; under saturating conditions, reaction rates were  
 comparable to those of putrescine. Compds. which were identified as  
 substrates of spermidine synthase in vitro formed derivs. of spermidine  
 and spermine in vivo. However, compds. such as 1-methylputrescine formed  
 in vivo only a spermidine derivative, because the 2nd aminopropylation was  
 sterically hindered by the substituent on the C atom next to the amino  
 group. The administration of 2-hydroxyputrescine to  
 $\alpha$ -difluoromethylornithine-pretreated chick embryos produced  
 spermidine and spermine analogs in amts. exceeding spermidine and spermine  
 formation from putrescine under comparable conditions. Since the concentration  
 of 2-hydroxyputrescine in the embryo was higher than that of

putrescine and all other putrescine analogs, uptake of the polyamine precursor from the yolk may be rate-limiting. Three days after administration of 5 mM  $\alpha$ -difluoromethylornithine, there was a near-to-complete arrest of embryonal growth. A series of diamines supported growth under these conditions, even if they were not substrates of spermidine synthase. The survival of chick embryos was, however, only supported if the diamines were capable of forming significant amounts of spermidine and spermine analogs.


IT 70052-12-9, DL- $\alpha$ -Difluoromethylornithine

RL: BIOL (Biological study)

(chick embryo response to, putrescine analogs effect on)

RN 70052-12-9 CAPLUS

CN Ornithine, 2-(difluoromethyl)- (9CI) (CA INDEX NAME)



=>

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1997:98548 CAPLUS  
DOCUMENT NUMBER: 126:207158  
TITLE: A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents  
AUTHOR(S): Cushion, Melanie T.; Chen, Franklin; Kloepfer, Natalie  
CORPORATE SOURCE: Dep. Internal Med., Univ. Cincinnati Coll. Med., Cincinnati, OH, 45627-0560, USA  
SOURCE: Antimicrobial Agents and Chemotherapy (1997), 41(2), 379-384  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A series of over 60 agents representing several different classes of compds. were evaluated for their effects on the ATP pools of Pneumocystis carinii populations derived from immunosuppressed rats. A cytotoxicity assay based on an ATP-driven bioluminescent reaction was used to determine the concentration of agent which decreased the *P. carinii* ATP pools by 50% vs. untreated controls (IC50). A ranking system based on the IC50 values was devised for comparison of relative responses among the compds. evaluated in the cytotoxic assay and for comparison to *in vivo* efficacy. With few exceptions, there was a strong correlation between results from the ATP assay and the performance of the compound *in vivo*. Antibiotics, with the exception of trimethoprim-sulfamethoxazole (TMP-SMX), were ineffective at reducing the ATP pools and were not active, clin. or in the rat model of *P. carinii* pneumonia. Likewise, other agents not expected to be effective, e.g., antiviral compds., did not show activity. Standard anti-*P. carinii* compds., e.g., TMP-SMX, pentamidine, and dapsone, dramatically reduced ATP levels. Analogs of the quinone and topoisomerase inhibitor groups were shown to reduce ATP concns. and hold promise for further *in vivo* investigation. The cytotoxicity assay provides a rapid assessment of response, does not rely on replicating organisms, and should be useful for assessment of structure-function relationships.


IT 70052-12-9, DFMO

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents)

RN 70052-12-9 CAPLUS

CN Ornithine, 2-(difluoromethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 \*STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 14:49:54 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 314 TO ITERATE

100.0% PROCESSED 314 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

L2 1 SEA SSS FUL L1

L3 2 L2

=> d 1-2 ibib abs hitstr

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:263671 CAPLUS

DOCUMENT NUMBER: 142:463986

TITLE: Catalytic hydrogenation of ethyl 2-amino-2-difluoromethyl-4-cyanobutanoate and its Schiff base reaction modes

AUTHOR(S): Zhu, Jingyang; Price, Benjamin A.; Walker, Jonathan; Zhao, Shannon X.

CORPORATE SOURCE: Process Research & Development, Bristol-Myers Squibb Company, New Brunswick, NJ, 08903, USA

SOURCE: Tetrahedron Letters (2005), 46(16), 2795-2797  
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Under heterogeneous catalysis, 2-amino-2-[di(fluoro)methyl]-4-(cyano)butanoic acid Et ester or its Schiff base could be selectively reduced in good yield by hydrogenation to give a diamine, or to form a five-membered ring or a six-membered ring heterocycles. This selectivity is highly dependent on the type of catalysts used. The hydrogenation of 2-amino-4-cyano-2-[di(fluoro)methyl]butanoic acid Et ester gave 2-[di(fluoro)methyl]ornithine Et ester dihydrochloride. The hydrogenation of a Schiff base derivative, 4-cyano-2-[di(fluoro)methyl]-2-[[di(phenyl)methylene]amino]butanoic acid Et ester using Raney cobalt gave

3-amino-3-[di(fluoro)methyl]-2-piperidinone.


IT 501011-46-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(study of hydrogenation of (amino)(cyano)[di(fluoro)methyl]butanoic acid ester using com. catalysts and differing reaction conditions)

RN 501011-46-7 CAPLUS

CN Butanoic acid, 2-amino-4-cyano-2-(difluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202415 CAPLUS

DOCUMENT NUMBER: 138:221839

TITLE: Processes for the production of  $\alpha$ -difluoromethyl ornithine (DFMO)

INVENTOR(S): Zhu, Jingyang; Chadwick, Scott T.; Price, Benjamin A.; Zhao, Shannon X.; Costello, Carrie A.; Vemishetti, Purushotham

PATENT ASSIGNEE(S): Women First Healthcare, Inc., USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020209	A2	20030313	WO 2002-US26990	20020823
WO 2003020209	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003083384	A1	20030501	US 2002-224890	20020819
US 6730809	B2	20040504		
CA 2457854	AA	20030313	CA 2002-2457854	20020823
EP 1421058	A2	20040526	EP 2002-768695	20020823
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
NZ 531331	A	20040625	NZ 2002-531331	20020823
BR 2002012153	A	20040713	BR 2002-12153	20020823
JP 2005501881	T2	20050120	JP 2003-524523	20020823
US 2004171876	A1	20040902	US 2004-788728	20040226
PRIORITY APPLN. INFO.:			US 2001-315832P	P 20010829
			US 2002-224890	A1 20020819
			WO 2002-US26990	W 20020823

OTHER SOURCE(S): CASREACT 138:221839; MARPAT 138:221839

AB Processes and synthetic intermediates for the preparation of H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(CHF<sub>2</sub>)(NH<sub>2</sub>)CO<sub>2</sub>H (DFMO) are described. Thus, condensation of glycine Et ester hydrochloride with benzaldehyde (MgSO<sub>4</sub>/Et<sub>3</sub>N/MeCN), addition reaction with acrylonitrile (K<sub>2</sub>CO<sub>3</sub>/Et<sub>3</sub>N+CH<sub>2</sub>Ph Cl<sup>-</sup>), reaction with ClCHF<sub>2</sub> (LiOBu-t/THF), and deprotection (4 N HCl/MTBE) yielded


NCCH<sub>2</sub>CH<sub>2</sub>C(CHF<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>CO<sub>2</sub>H. Hydrogenolysis over 10% Pd/C in MTBE and treatment with 12 N HCl afforded DFMO.HCl (.apprx. 75 % pure by <sup>1</sup>H NMR).

IT 501011-46-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(production of  $\alpha$ -difluoromethyl ornithine)

RN 501011-46-7 CAPLUS

CN Butanoic acid, 2-amino-4-cyano-2-(difluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



=>